Skeletal complications in cancer patients with bone metastases

International Journal of Urology - Tập 23 Số 10 - Trang 825-832 - 2016
Shunsuke Tsuzuki1, Sun Hee Park1, Matthew R. Eber1, Christopher M. Peters2, Yusuke Shiozawa1
1Department of Cancer Biology and Comprehensive Cancer Center, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA
2Department of Anesthesiology, Wake Forest School of Medicine , Winston-Salem, North Carolina, USA

Tóm tắt

AbstractAs a result of significant improvements in current therapies, the life expectancy of cancer patients with bone metastases has dramatically improved. Unfortunately, these patients often experience skeletal complications that significantly impair their quality of life. The major skeletal complications associated with bone metastases include: cancer‐induced bone pain, hypercalcemia, pathological bone fractures, metastatic epidural spinal cord compression and cancer cachexia. Once cancer cells invade the bone, they perturb the normal physiology of the marrow microenvironment, resulting in bone destruction, which is believed to be a direct cause of skeletal complications. However, full understanding of the mechanisms responsible for these complications remains unknown. In the present review, we discuss the complications associated with bone metastases along with matched conventional therapeutic strategies. A better understanding of this topic is crucial, as targeting skeletal complications can improve both the morbidity and mortality of patients suffering from bone metastases.

Từ khóa


Tài liệu tham khảo

10.1016/j.eururo.2013.09.024

10.1038/nature04872

10.1007/s10555-012-9373-9

10.1615/CritRevOncog.2015013668

10.1158/0008-5472.CAN-13-2645

10.1172/JCI43414

10.1016/j.ccell.2014.11.017

10.1677/erc.1.00543

10.1093/annonc/mdu103

10.1093/annonc/mdm056

10.1002/(SICI)1097-0142(19971015)80:8 <1588::AID-CNCR9>3.0.CO;2-G

10.1111/j.1749-6632.2009.05429.x

10.1007/s10555-006-9033-z

10.1016/j.expneurol.2004.11.028

10.1016/j.bbamem.2015.02.004

10.1523/JNEUROSCI.3815-04.2005

10.1097/SPC.0000000000000048

10.1016/0885-3924(96)00099-1

10.1111/j.1533-2500.2001.01025.x

10.3389/fphar.2016.00042

10.1177/0269216311428528

10.1200/JCO.2006.09.5281

10.1016/j.ijrobp.2010.11.026

10.1093/annonc/mds233

10.1002/pds.1782

10.1038/35093019

Sabino MA, 2002, Simultaneous reduction in cancer pain, bone destruction, and tumor growth by selective inhibition of cyclooxygenase‐2, Cancer Res., 62, 7343

10.1111/papr.12342

10.1523/JNEUROSCI.13-05-02136.1993

10.1213/01.ane.0000275190.42912.37

10.1016/j.cell.2009.09.028

10.1002/ana.410360221

10.1212/WNL.48.2.501

10.1158/0008-5472.CAN-05-0826

10.1016/j.jpain.2010.12.016

10.1158/0008-5472.CAN-07-1183

10.1056/NEJMoa0901510

10.1016/j.jpain.2012.05.006

10.1002/art.37950

10.1016/j.pain.2011.05.003

10.1097/j.pain.0000000000000211

10.1007/s13277-011-0299-6

10.1046/j.1464-410X.2000.00063.x

10.1016/j.neuroscience.2004.04.027

10.1523/JNEUROSCI.21-03-00999.2001

10.1523/JNEUROSCI.21-23-09355.2001

10.1073/pnas.1830978100

Qiao L, 2015, Endothelin‐A receptor antagonists in prostate cancer treatment‐a meta‐analysis, Int. J. Clin. Exp. Med., 8, 3465

10.1002/cncr.27674

10.1002/cncr.22996

10.1016/j.regpep.2010.03.004

10.1111/pme.12157

10.1002/j.1532-2149.2012.00269.x

10.1111/pme.12258

10.1111/pme.12063

10.1002/(SICI)1521-1878(199810)20:10<837::AID-BIES9>3.0.CO;2-D

10.1016/S1471-4892(01)00014-5

10.1007/s00774-006-0734-8

10.1126/science.289.5484.1508

10.1359/jbmr.2000.15.8.1467

10.1093/jnci/94.19.1458

10.1016/S0022-5347(17)40597-0

Strang P, 1997, The analgesic efficacy of clodronate compared with placebo in patients with painful bone metastases from prostatic cancer, Anticancer Res., 17, 4717

10.1038/bjc.1997.488

Luger NM, 2001, Osteoprotegerin diminishes advanced bone cancer pain, Cancer Res., 61, 4038

10.1158/1078-0432.CCR-10-2507

10.1016/S0140-6736(10)62344-6

10.1200/JCO.2010.29.7101

10.1002/cncr.27789

10.1073/pnas.95.23.13453

10.1158/0008-5472.CAN-06-3940

10.3816/CBC.2010.n.059

10.1007/s00198-014-2944-6

10.1056/NEJMcp042806

10.1172/JCI115947

10.1074/jbc.272.32.20125

10.1126/science.3685994

10.1073/pnas.89.7.2732

10.1097/MED.0b013e32834b4401

10.7326/0003-4819-112-7-499

Hosking DJ, 1981, Rehydration in the treatment of severe hypercalcaemia, Q J Med., 50, 473

10.2217/fon.15.232

10.1210/jc.2014-1001

Sternlicht H, 2015, Hypercalcemia of malignancy and new treatment options, Ther. Clin. Risk Manag., 11, 1779

10.1080/10606820213681

10.2106/00004623-199706000-00018

10.1302/0301-620X.84B4.12495

10.1007/s00264-006-0205-9

10.1016/j.injury.2015.07.028

10.2106/00004623-197052040-00002

Snell W, 1964, Femoral metastases and fractures from breast cancer, Surg. Gynecol. Obstet., 119, 22

10.1097/00003086-199002000-00036

10.3109/17453678809169697

10.1302/0301-620X.86B4.14703

Ristevski B, 2009, Mortality and complications following stabilization of femoral metastatic lesions: a population‐based study of regional variation and outcome, Can. J. Surg., 52, 302

10.1097/01.blo.0000093057.96273.fb

10.7150/jca.13377

10.1016/S1470-2045(05)70022-X

10.1016/S1474-4422(08)70089-9

10.1212/WNL.27.5.422

10.1148/107.1.99

10.3171/jns.1985.63.2.0260

10.3892/ol.2014.2795

10.1016/S0959-8049(05)80011-5

10.1016/S0140-6736(05)66954-1

10.1016/S0959-8049(97)10090-9

10.1016/S0303-7207(01)00496-8

10.1002/jbm.a.31085

10.1073/pnas.0505996102

10.1038/nm.3961

Thông tin
Thông tin xuất bản

International Journal of Urology

Tập 23 Số 10

825-832

Thông tin tác giả